Back to News
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
Source: PR Newswire
Healthcare & Biotech
The available article text identifies Innovent Biologics as a biopharmaceutical company focused on researching, developing, manufacturing, and commercializing drugs for major diseases, including oncology and autoimmune conditions. The text is truncated before any announcement, figures, or market-relevant development is provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- ArriVent reports phase 1 data for cancer drug ARR-217
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- UK immigration crackdown threatens £15 billion care sector
- US Midterm Elections 2026: Key Issues, From Affordability to AI
- Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product